Аннотация
e13596 Background: Cervical cancer is the second most common type of gynecological cancer worldwide. Nearly all cases are associated with high-risk human papillomaviruses (hrHPV). Data on the epidemiology of HPV in Kazakhstan and Central Asia are limited. Our study was carried out to determine the prevalence of hrHPV and abnormal pap results associated with HPV positivity in women attending gynecological outpatient units. Methods: We prospectively recruited 1,800 women at gynecology outpatient units in four large regions of Kazakhstan in 2015. Study participants did not have a known history of HPV infection. Co-testing for pap smear and a short survey obtained in all cases. Final analyses included 1,730 cases. 70 cases were excluded due to missing data. The HPV test samples were screened in South Korea with DNA Chip test with hrHPV genotyping in all positive cases. Pap smears reviewed at cytology laboratory at the Institute of Oncology, Kazakhstan. Results: The mean age of the study group was 40.0±9.8 years (range 18-65 years. Prevalence of HPV was 27.8% (481 cases) and cytology abnormalities were present in 40.5% (702 cases). HPV infection found more often in young women under the age of 25 (46.4%, p < 0.01). ASCUS was also more commonly reported in this age group (p = 0.029). HrHPV prevalence in women aged 25 to 35 yeas and higher varied between 25.7% to 28.3% and had no statistical difference. The pap-test results were in opposite to HPV prevalence whereas severity of abnormalities increased with age. LSIL in the age group of 46-55 years was more common than in 56 years and older population and represented 7.8% and 8.3% respectively (p < 0.05). The HSIL diagnosed more often in women above 56 years and accounted for 2.5%.. One case of cervical cancer was found in all study population. Conclusions: For our best knowledge this is the largest study focusing on hrHPV prevalence and abnormal cytology in Kazakhstani women. Our results are in accordance with other related data from similar studies. Data suggest benefit of targeting cytology based screening for women under 30 years of age and HPV based screening for older women population instead of “one size fits all” approach.